Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
This ESMO Clinical Practice Guideline provides key recommendations and algorithms for the management of patients with EBC.
23P Consensus statements and expert recommendations for BRCAm breast cancer in the Asia-Pacific region (STREAM-AP)
This modified Delphi consensus addresses practical gaps in genetic counselling and testing, risk assessment, and management of germline BRCA mutations (gBRCAm)-associated breast cancer (BC) in the Asia-Pacific region.
Molecular tumour boards — current and future considerations for precision oncology
Herein, we discuss the evolving role of MTBs and current and future considerations for their use in precision oncology.
Molecular tumour boards — current and future considerations for precision oncology Read More »
Development of a Breast Cancer Risk Prediction Model Incorporating Polygenic Risk Scores and Nongenetic Risk Factors for Korean Women
To develop a breast cancer prediction model for Korean women using published polygenic risk scores (PRS) combined with nongenetic risk factors (NGRF).
Usefulness and real-world outcomes of next generation sequencing testing in patients with cancer: an observational study on the impact of selection based on clinical judgement
Next Generation Sequencing (NGS) panels are increasingly used in advanced patients with cancer to guide therapy. There is, however, controversy about when should these panels be used, and about their impact on the clinical course.
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer
The aim of these guidelines is to provide guidance for the harmonisation of the management of patients with MBC across the different regions of Asia, drawing from data provided by global and Asian trials whilst at the same time integrating the differences in genetics, demographics and scientific evidence, together with restricted access to certain therapeutic strategies.
Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type
This review emphasizes the recent progress made with the precision-medicine therapy of metastatic breast cancer and TNBC.
Targeting HER2-positive breast cancer: advances and future directions
This Review discusses the current standards of care for HER2-positive breast cancer, mechanisms of resistance to HER2-targeted therapy and new therapeutic approaches and agents, including strategies to harness the immune system.
Targeting HER2-positive breast cancer: advances and future directions Read More »
Genomics to select treatment for patients with metastatic breast cancer
This trial provides evidence that the treatment decision led by genomics should be driven by a framework of target actionability in patients with metastatic breast cancer.
Genomics to select treatment for patients with metastatic breast cancer Read More »
Update on the Recommendations on Breast Cancer Screening by the Cancer Expert Working Group on Cancer Prevention and Screening
After consideration of the most recent international and local scientific evidence including findings of the HKBCS, the Cancer Expert Working Group on Cancer Prevention and Screening (CEWG) has reviewed and updated its BC screening recommendations.